SVRA - サバラ (Savara Inc.) サバラ

 SVRAのチャート


 SVRAの企業情報

symbol SVRA
会社名 Savara Inc (サバラ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Savara Inc. formerly Mast Therapeutics Inc. is an orphan lung disease company. The Company is engaged in the development and commercialization of novel therapeutics to address unmet medical needs. Its product pipeline include Molgradex AeroVanc and Aironite. Molgradex is an inhaled formulation of recombinant human GM-CSF. It is developing Molgradex for the treatment of pulmonary alveolar proteinosis (PAP) and nontuberculous mycobacterial (NTM) lung infection. AeroVanc is a vancomycin hydrochloride inhalation powder. It is developing AeroVanc as an antibiotic for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infection in individuals living with cystic fibrosis (CF). Aironite is a sodium nitrite inhalation solution. Aironite is an investigational product. The Company is developing Molgradex in a pivotal Phase-III clinical trial for the treatment of PAP and in a Phase II a study for NTM lung infection. AeroVanc is in a Phase-III clinical trial.   サバラは米国のバイオ医薬品企業。臨床段階で、致命的な病気や重病に対する医薬品の開発に従事する。同社は心臓麻痺の治療用の医薬品候補として、噴霧状の亜硝酸ナトリウム「AIR001」や、浄化されたPoloxamer 188である「Velopoxamer」を開発する。本社はカリフォルニア州サンディエゴ。   Savara is an orphan lung disease company. Its lead program, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Its management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization.
本社所在地 6836 Bee Cave Road Building III Suite 200 Austin TX 78746 USA
代表者氏名 Robert N. Neville ロバート・N・ネヴィル
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +1 512-614-1848
設立年月日 35034
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 24人
url www.masttherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/svra
adr_tso
EBITDA EBITDA(百万ドル) -37.52100
終値(lastsale) 10.34
時価総額(marketcap) 362874793.16
時価総額 時価総額(百万ドル) 333.04460
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 273.60560
当期純利益 当期純利益(百万ドル) -54.56400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Savara Inc revenues was not reported. Net loss applicable to common stockholders increased from $17.5M to $38.4M. Higher net loss reflects Impairment of acquired IPR&D increase from $0K to $21.7M (expense) Research and development - Balancing val increase from $7M to $17.4M (expense) Stock-based Compensation in R&D increase from $74K to $373K (expense).

 SVRAのテクニカル分析


 SVRAのニュース

   Stocks Volume Buzz: Savara Inc. (NASDAQ:SVRA), Solitario Zinc Corp. (AMEX:XPL)  2021/07/06 04:26:42 Stock Equity
Savara Inc. (NASDAQ:SVRA) with the stream of -3.05% also noticed, India Solitario Zinc Corp. (AMEX:XPL) encountered a rapid change of 1.75% in the last hour of Mondays trading session. Savara The post Stocks Volume Buzz: Savara Inc. (NASDAQ:SVRA), Solitario Zinc Corp. (AMEX:XPL) appeared first on Stocks Equity .
   Savara doses first patient in late-stage rare lung disease trial  2021/06/30 14:54:20 Seeking Alpha
   Savara Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial  2021/06/30 14:47:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the first patient has been dosed in the pivotal IMPALA-2 clinical trial. IMPALA-2 is a Phase 3 trial designed to evaluate the efficacy and safety of molgramostim compared to placebo. Molgramostim is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). The trial is expected to be conduct
   Stock Runner: Savara Inc. (NASDAQ:SVRA), Blonder Tongue Laboratories, Inc. (AMEX:BDR)  2021/06/18 23:06:00 Stock Equity
Savara Inc. (NASDAQ:SVRA) with the stream of -1.09% also noticed, India Blonder Tongue Laboratories, Inc. (AMEX:BDR) encountered a rapid change of 0.00% in the last hour of Fridays trading session. The post Stock Runner: Savara Inc. (NASDAQ:SVRA), Blonder Tongue Laboratories, Inc. (AMEX:BDR) appeared first on Stocks Equity .
   Savara: They Failed Once, But They Are Trying Again  2021/06/07 19:03:54 Seeking Alpha
   Savara doses first patient in late-stage rare lung disease trial  2021/06/30 14:54:20 Seeking Alpha
   Savara Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial  2021/06/30 14:47:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the first patient has been dosed in the pivotal IMPALA-2 clinical trial. IMPALA-2 is a Phase 3 trial designed to evaluate the efficacy and safety of molgramostim compared to placebo. Molgramostim is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). The trial is expected to be conduct
   Stock Runner: Savara Inc. (NASDAQ:SVRA), Blonder Tongue Laboratories, Inc. (AMEX:BDR)  2021/06/18 23:06:00 Stock Equity
Savara Inc. (NASDAQ:SVRA) with the stream of -1.09% also noticed, India Blonder Tongue Laboratories, Inc. (AMEX:BDR) encountered a rapid change of 0.00% in the last hour of Fridays trading session. The post Stock Runner: Savara Inc. (NASDAQ:SVRA), Blonder Tongue Laboratories, Inc. (AMEX:BDR) appeared first on Stocks Equity .
   Savara: They Failed Once, But They Are Trying Again  2021/06/07 19:03:54 Seeking Alpha
   Savara to Present at the Jefferies Virtual Healthcare Conference  2021/05/26 00:00:00 BioSpace
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Savara management will be presenting at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 10:00 AM ET / 7:00 AM PT.
   Stock Runner: Savara Inc. (NASDAQ:SVRA), Blonder Tongue Laboratories, Inc. (AMEX:BDR)  2021/06/18 23:06:00 Stock Equity
Savara Inc. (NASDAQ:SVRA) with the stream of -1.09% also noticed, India Blonder Tongue Laboratories, Inc. (AMEX:BDR) encountered a rapid change of 0.00% in the last hour of Fridays trading session. The post Stock Runner: Savara Inc. (NASDAQ:SVRA), Blonder Tongue Laboratories, Inc. (AMEX:BDR) appeared first on Stocks Equity .
   Savara: They Failed Once, But They Are Trying Again  2021/06/07 19:03:54 Seeking Alpha
   Savara to Present at the Jefferies Virtual Healthcare Conference  2021/05/26 00:00:00 BioSpace
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Savara management will be presenting at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 10:00 AM ET / 7:00 AM PT.
   Savara (SVRA) Received its Third Buy in a Row  2021/05/18 08:28:08 Smarter Analyst
After Piper Sandler and H.C. The post Savara (SVRA) Received its Third Buy in a Row appeared first on Smarter Analyst .
   Caxton Corp Buys Savara Inc, Kala Pharmaceuticals Inc, Ares Acquisition Corp, Sells XL Fleet ...  2021/05/17 17:38:29 GuruFocus
Related Stocks: KALA , FB , MA , WHR , SPGI , V , SVRA , AAC.U , AJAX , MRAC , ONCS , SR ,

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 サバラ SVRA Savara Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)